Amphastar Pharmaceuticals (AMPH) CEO Jack Y. Zhang Buys 25,000 Shares of Stock

Amphastar Pharmaceuticals (NASDAQ:AMPH) CEO Jack Y. Zhang acquired 25,000 shares of the stock in a transaction on Tuesday, May 15th. The shares were acquired at an average cost of $16.08 per share, for a total transaction of $402,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,065,619 shares in the company, valued at approximately $33,215,153.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of AMPH stock traded up $0.41 during mid-day trading on Friday, hitting $16.63. The stock had a trading volume of 253,659 shares, compared to its average volume of 195,509. Amphastar Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $20.45. The stock has a market capitalization of $745.83 million, a PE ratio of 43.76, a price-to-earnings-growth ratio of 2.39 and a beta of 1.42. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.53 and a current ratio of 2.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, May 9th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.13). Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. The firm had revenue of $58.40 million during the quarter, compared to analyst estimates of $60.75 million. During the same quarter last year, the business posted $0.09 EPS. The firm’s revenue was up 3.0% on a year-over-year basis. equities analysts forecast that Amphastar Pharmaceuticals will post 0.3 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in AMPH. Millennium Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 1,746.9% in the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock valued at $5,650,000 after purchasing an additional 277,771 shares during the period. Cortina Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $4,907,000. Mackay Shields LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $4,294,000. Dimensional Fund Advisors LP lifted its stake in shares of Amphastar Pharmaceuticals by 17.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after purchasing an additional 226,271 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Amphastar Pharmaceuticals by 156.1% in the fourth quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock valued at $3,392,000 after purchasing an additional 107,486 shares during the period. Hedge funds and other institutional investors own 44.94% of the company’s stock.

Several brokerages have issued reports on AMPH. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. BMO Capital Markets restated a “market perform” rating and issued a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 19th. Finally, Needham & Company LLC restated a “buy” rating and issued a $24.00 target price (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $21.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply